A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses-Reference-Cited by-同舟云学术

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Published:2017-08-07 Issue:4 Volume:103 Page:674-683
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Svensson Robin J.¹,Aarnoutse Rob E.²,Diacon Andreas H.³,Dawson Rodney⁴,Gillespie Stephen H.⁵,Boeree Martin J.⁶,Simonsson Ulrika S.H.¹

Affiliation:

1. Department of Pharmaceutical BiosciencesUppsala UniversityUppsala Sweden

2. Department of PharmacyRadboud University Medical CenterNijmegen the Netherlands

3. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research and MRC Centre for TB ResearchDivision of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa and TASK Applied SciencesCape Town South Africa

4. Department of Respiratory MedicineUniversity of Cape Town, Cape Town, South Africa and The Lung InstituteCape Town South Africa

5. School of MedicineUniversity of St. AndrewsSt. Andrews Fife UK

6. Department of Lung DiseasesRadboud University Medical Center, Nijmegen, the Netherlands and University Centre for Chronic Diseases DekkerswaldGroesbeek the Netherlands

Funder

Swedish Research Council

Bill and Melinda Gates Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.778

Reference38 articles.

1. History of the Development of Rifampin

2. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?